US 12234236

US patent 12234236, titled "GLP-1R agonist and therapeutic method thereof," was granted to Ascletis Pharma China Co Ltd.. The patent lists Bin Liang, Jinzi Jason Wu, and Bailing YANG as the inventors. The application was filed on September 13, 2024, and the patent was issued on February 25, 2025.

The abstract describes the present disclosure as GLP-1R modulating compounds that are useful for treating GLP-1R-mediated diseases or conditions.

Regarding the claims:
The complete text of the claims for US patent 12234236 is not present in the provided authoritative patent text. Therefore, a plain-language overview of each independent claim cannot be provided based solely on the given information. However, public records indicate that claims 1-9, 12-17, and 21-25 of US12234236B1 are currently being challenged.

Litigation Status:
As of April 26, 2026, US patent 12234236 is involved in Post-Grant Review (PGR) case number PGR2025-00057 before the Patent Trial and Appeal Board (PTAB) of the USPTO. The petitioner in this case is CONJUPRO BIOTHERAPEUTICS, INC., challenging the patent owner, ASCLETIS PHARMA CHINA CO. LTD.. The legal status is "Active," and the PTAB case is listed as "Pending - Instituted". There is no information from the search results indicating that this patent is currently involved in a case before the Court of Appeals for the Federal Circuit (CAFC) in 2026.

Known litigation involving US patent 12234236 includes the following:

Case 1:

• Plaintiff(s): CONJUPRO BIOTHERAPEUTICS, INC.
• Defendant(s): Ascletis Pharma China Co Ltd
• Jurisdiction: Patent Trial and Appeal Board (PTAB)
• Case Number: PGR2025-00057
• Filing Date: June 20, 2025
• Outcome or Current Status: Pending - Instituted

Proceedings overview

There is one AIA trial proceeding on file for US Patent 12234236. This is a Post-Grant Review (PGR) that has been instituted and is currently pending. This means the patent's claims are actively being challenged, and a final decision on their patentability has not yet been issued. For a defendant, this indicates the patent is currently vulnerable, and the outcome of this PGR will significantly impact its strength.

PGR2025-00057 — Conjupro Biotherapeutics, Inc. et al. v. Ascletis Pharma China Co Ltd

• Type: Post-Grant Review
• Filed: 2025-06-20
• Status: Trial Instituted — The PTAB has decided to proceed with a review of the challenged claims.
• Judge panel: Not publicly available from the provided search results. However, other cases with Judge Jeffrey N. Fredman and Judge John G. New are listed as active in the Unified Patents Portal.
• Petition grounds: The petition challenges claims directed to compounds that modulate the GLP-1 receptor. Specifically, it identifies independent Markush claims 1 and 24, which include compounds such as Compound 1, Compound 19, Compound 20, and Compound 65. The petitioner argues obviousness under 35 U.S.C. § 103, particularly focusing on the known GLP-1R agonist orforglipron (Eli Lilly & Co.). The petition asserts that a person of ordinary skill in the art would have been motivated to modify orforglipron, for example, by replacing a methyl group with a cyclopropyl group, based on teachings from prior art references such as Yoshino, Kawai, and Talele.
• Institution decision: Instituted. The exact date of institution is not provided, but the proceeding status is "Trial Instituted." The PTAB's decision to institute was based on the petitioner's arguments regarding the obviousness of the challenged claims in light of prior art, including orforglipron and other references discussing substitutions that preserve or enhance biological activity.
• Final Written Decision: Not yet issued. Final written decisions in PGRs are expected between June and November 2026.
• Settlement / termination: Not settled or terminated.
• Appeal: No Federal Circuit appeal has been filed as a Final Written Decision has not been issued. Appeals to the Federal Circuit typically occur after a Final Written Decision.
• Defensive value: This active PGR indicates that the patentability of claims 1 and 24, along with dependent claims, is currently under scrutiny. If these claims are ultimately canceled, any infringement assertions based on them would be significantly weakened. Defendants should closely monitor the progress and outcome of this proceeding.

Strategic summary

US Patent 12234236 is currently facing a Post-Grant Review, PGR2025-00057, initiated by Conjupro Biotherapeutics, Inc. et al. The PTAB has instituted the trial, meaning the patent's claims 1 and 24, along with associated dependent claims, are being challenged for obviousness under 35 U.S.C. § 103. The core of the petitioner's argument revolves around the known GLP-1R agonist orforglipron and the asserted obviousness of modifications to its structure, such as the replacement of a methyl group with a cyclopropyl group, based on existing chemical knowledge and other prior art.

As of the current date, no Final Written Decision has been issued. Therefore, no claims of US12234236 have been canceled or sustained through this proceeding. All claims remain "untested" in terms of a final PTAB ruling. The institution of the trial, however, signals that the PTAB found a reasonable likelihood that the petitioner would prevail on at least one challenged claim. The estoppel landscape is not yet fully formed since there is no Final Written Decision. However, if the petitioner proceeds to a Final Written Decision, they (and their privies) would be estopped from raising any grounds they raised or reasonably could have raised in the PGR. There is no information to suggest a pattern of multiple PGRs by the same petitioner on this specific patent, nor aggressive PTAB appeals by the patent owner at this stage.

Recommended next steps

Since PGR2025-00057 is currently instituted and pending, a defendant facing assertion of US12234236 should:

• Closely monitor the progress of PGR2025-00057. Final Written Decisions in PGRs are expected between June and November 2026.
• Be aware that the Director of the USPTO now directly determines whether to institute IPR and PGR proceedings, and can issue summary notices denying institution without explanation, or detailed decisions for novel issues.
• Review the petition and the Patent Owner's response in PGR2025-00057 to understand the specific arguments and evidence being presented regarding obviousness. This will provide insight into the potential weaknesses of the challenged claims.
• Prepare for the possibility that claims 1 and 24, and potentially dependent claims, may be found unpatentable in the upcoming Final Written Decision.

Inventors

• Bin Liang (Ascletis Pharma China Co Ltd)
• Jinzi Jason Wu (Ascletis Pharma China Co Ltd)
• Bailing YANG (Ascletis Pharma China Co Ltd)

Original assignee

The original assignee, Ascletis Pharma China Co Ltd, is a biopharmaceutical company. Based on the patent title, "GLP-1R agonist and therapeutic method thereof," their primary line of business appears to be the research, development, and commercialization of therapeutic compounds, specifically GLP-1R agonists. While the patent describes compounds useful for treating GLP-1R-mediated diseases, the provided information does not explicitly state whether Ascletis Pharma China Co Ltd has shipped a product embodying the claims. The current status of Ascletis Pharma China Co Ltd is "Active".

Assignment timeline

Ascletis Pharma China Co Ltd is a biopharmaceutical company headquartered in Hangzhou, China, with operations focused primarily in mainland China. The company develops small-molecule and peptide therapeutics for metabolic diseases, infectious diseases, and other specialty indications. Ascletis Pharma has developed and marketed antiviral medicines, including danoprevir for hepatitis C, and has an authorized ritonavir tablet in China. They are actively involved in the development of GLP-1R agonists, including an oral small molecule GLP-1R agonist called ASC30, which has completed enrollment in a U.S. Phase II study for diabetes. The company's stock is listed on the Hong Kong Stock Exchange.

The USPTO Assignment Center (https://assignmentcenter.uspto.gov/) was searched for US patent 12234236. As of May 18, 2026, there are no recorded assignments for US Patent 12234236 in the USPTO Assignment Center. This indicates that the original assignee, Ascletis Pharma China Co Ltd, still owns the patent.

Timeline diagram

timeline
    title Ownership of US 12234236
    2024 : Application filed by Ascletis Pharma
    2025 : Issued to Ascletis Pharma

NPE / troll-pattern signals

1. Shell-entity transfer — not present. The patent remains with the original operating company, Ascletis Pharma China Co Ltd.
2. Known asserter in the chain — not present. The current owner, Ascletis Pharma China Co Ltd, is a publicly traded biopharmaceutical company.
3. Repeat correspondent across the chain — not present. There are no recorded assignments in the chain.
4. Cascading transfers — not present. There are no recorded assignments.
5. Pre-litigation transfer — not present. There are no recorded assignments. The current PGR challenge was filed while the patent is still owned by the original assignee.
6. Bankruptcy fire-sale — not present. Ascletis Pharma China Co Ltd is an active, publicly traded company.
7. Privateering — unclear. While Ascletis Pharma China Co Ltd is an operating company, without specific SEC filings or reports detailing assertion agreements, it's impossible to confirm or deny privateering.
8. Defensive aggregator (anti-NPE) — not present. The patent is owned by an operating company, not a defensive aggregator.

Verdict

Insufficient data. There are no recorded assignments for US patent 12234236 in the USPTO Assignment Center. The patent remains with the original assignee, Ascletis Pharma China Co Ltd, which is an operating biopharmaceutical company. Therefore, there is no evidence of an NPE / patent-troll pattern in the ownership chain.

The USPTO database search for US patent 12234236 revealed several prior art citations. The provided context includes details from the patent itself and information regarding the ongoing Post-Grant Review (PGR) case PGR2025-00057, which specifically discusses prior art in relation to claims 1 and 24.

Here's an analysis of the most relevant prior art, focusing on the information available and the context of the PGR challenge:

Most Relevant Prior Art

The most relevant prior art explicitly mentioned in the context of the PGR challenge is orforglipron (Eli Lilly & Co.).

• Full Citation: Orforglipron (Eli Lilly & Co.) is frequently referenced in the context of the PGR, specifically in relation to the patent owner's preliminary response and the petitioner's arguments. While a specific patent number for orforglipron isn't provided in the immediate context, its existence and properties are central to the obviousness challenge.
• Publication/Filing Date: By 2023, it was known that orforglipron possessed GLP-1 receptor agonistic activity.
• Brief Description: Orforglipron is described as an orally bioavailable, non-peptidic small-molecule GLP-1R agonist developed by Eli Lilly & Co. It exhibits full agonist efficacy, promoting cAMP accumulation at levels comparable to native GLP-1, with an EC50 of 1.1 nM at both human and cynomolgus monkey GLP-1 receptors. It was structurally optimized for once-daily oral administration, addressing compliance issues associated with injectable therapies for type 2 diabetes and obesity.
• Claims Potentially Anticipated (35 U.S.C. § 102): The petitioner in PGR2025-00057 argues that claims 1 and 24, and potentially other dependent claims (1-9, 12-17, and 21-25), are obvious over prior art including orforglipron. The argument centers on the motivation a person of ordinary skill in the art would have had to modify orforglipron, for example, by replacing a methyl group with a cyclopropyl group, based on teachings from prior art references such as Yoshino, Kawai, and Talele (not fully detailed here, but mentioned in the PGR context).

Other Cited Patent Art (from Google Patents listing for US12234236B1)

The Google Patents page for US12234236B1 lists numerous patent citations. While a full analysis of each is beyond the scope of providing "most relevant" without further detail on their content and specific relevance to the claims, here are a few examples found that are listed as citing US12234236B1, or being cited by it. Please note the distinction between "cited by" and "patent citations" which are typically prior art cited against the patent. The prompt specifically asks for "patent citations for 12234236".

• WO2018056453A1 (Yoshino et al.):

  • Full Citation: WO2018056453A1 - Pyrazolopyridine derivative having glp-1 receptor agonist effect.
  • Publication Date: Published March 29, 2018 (priority date September 14, 2016).
  • Brief Description: This patent describes compounds with an indole ring or a pyrrolo[2,3-b]pyridine ring and a pyrazolopyridine skeleton that act as GLP-1 receptor agonists. It aims to provide compounds with improved activity, metabolic stability, and bioavailability for non-invasive administration in treating type 2 diabetes and obesity.
  • Claims Potentially Anticipated: The PGR mentions "Yoshino" as a reference for motivating modifications to orforglipron. This suggests WO2018056453A1 could potentially be used to demonstrate obviousness of certain structural features or the GLP-1R agonist activity, particularly for claims relating to compounds with similar core structures or therapeutic applications. Since claims 1-9, 12-17, and 21-25 are challenged for obviousness, this reference would likely be considered against those.

• US20230150998A1 (Reeves et al.):

  • Full Citation: US20230150998A1 - Compounds as glp-1r agonists.
  • Publication Date: Published May 11, 2023 (priority date September 27, 2021).
  • Brief Description: This application provides compounds that may be used as GLP-1R agonists, or pharmaceutically acceptable salts thereof, along with pharmaceutical compositions and methods of their use to treat GLP-1R-mediated diseases. It describes heterocyclic GLP-1 agonists.
  • Claims Potentially Anticipated: Given the similar subject matter of GLP-1R agonists and methods of treatment, this patent application could potentially anticipate or render obvious claims related to the compounds themselves (e.g., claims 1 and 24, and dependent claims) or the therapeutic methods (e.g., method claims discussed in the patent's summary).

• US20220213130A1 (Meng et al.):

  • Full Citation: US20220213130A1 - Heterocyclic glp-1 agonists.
  • Publication Date: Published July 7, 2022 (priority date December 28, 2020).
  • Brief Description: This patent application also describes heterocyclic GLP-1 agonists. It provides definitions for various chemical groups including cycloalkyl and heterocyclyl.
  • Claims Potentially Anticipated: Similar to US20230150998A1, this reference could be used to challenge claims 1 and 24, and related dependent claims, particularly concerning the heterocyclic nature of the compounds and their GLP-1R agonist activity.

Non-Patent Citations (as mentioned in US12291530B1 which cites US12234236B1)

While the prompt specifically asks for patent citations, it's worth noting that non-patent literature is also crucial in prior art analysis. For instance, WO2023220112A1, which cites US12234236B1, mentions the non-patent citation:

• Kawai Takahiro et al. "Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist" (2020):
  • Publication Date: November 24, 2020.
  • Brief Description: This publication discusses the structural basis for GLP-1 receptor activation by LY3502970, which is an orally active nonpeptide agonist.
  • Claims Potentially Anticipated: This type of publication could provide evidence of the state of the art regarding orally active nonpeptide GLP-1R agonists prior to the priority date of US12234236, potentially impacting claims related to the chemical structures and their activity, contributing to an obviousness argument for claims 1 and 24 and associated dependent claims.

The obviousness analysis under 35 U.S.C. § 103 for US patent 12234236 is conducted based on the arguments presented in the Post-Grant Review (PGR) case PGR2025-00057, as the complete text of the patent's claims is not provided in the authoritative document. This analysis will interpret the petitioner's arguments as indicative of how a Person Having Ordinary Skill in the Art (PHOSITA) would perceive the inventiveness of the claimed subject matter.

Obviousness Analysis under 35 U.S.C. § 103

Challenged Claims and Primary Prior Art:
The Post-Grant Review (PGR2025-00057) challenges independent Markush claims 1 and 24, along with associated dependent claims, which are directed to GLP-1R modulating compounds, including specific examples such as Compound 1, Compound 19, Compound 20, and Compound 65.

The primary prior art reference identified in the petition is orforglipron, a known GLP-1R agonist developed by Eli Lilly & Co.

Proposed Modification and Secondary Prior Art:
The petitioner's argument centers on the idea that a PHOSITA would have been motivated to modify orforglipron. Specifically, the challenge asserts obviousness for modifications such as "replacing a methyl group with a cyclopropyl group." This proposed modification is alleged to be taught or suggested by prior art references including Yoshino, Kawai, and Talele.

Motivation for Combination (PHOSITA Perspective):

A PHOSITA, seeking to develop or improve GLP-1R agonists, would start with known active compounds like orforglipron. The motivation to modify such a lead compound typically arises from a desire to enhance desirable properties (e.g., potency, selectivity, pharmacokinetic profile, metabolic stability) or to overcome liabilities (e.g., side effects, poor bioavailability).

In this context, the petitioner argues that a PHOSITA would have been motivated to replace a methyl group present in orforglipron with a cyclopropyl group. This motivation is asserted to stem from the collective teachings of references such as Yoshino, Kawai, and Talele. The PTAB's decision to institute the trial indicates that these arguments provided a "reasonable likelihood" of success, suggesting the Board recognized plausible motivations for such modifications in the art.

The specific motivations for replacing a methyl group with a cyclopropyl group, as implied by the institution of the PGR, could include:

1. Bioisosteric Replacement: Cyclopropyl groups are often considered bioisosteric replacements for methyl or isopropyl groups in medicinal chemistry. Such replacements can sometimes lead to improved metabolic stability due to reduced susceptibility to oxidative metabolism, altered lipophilicity, or modified steric interactions with target receptors or enzymes, potentially enhancing the compound's half-life or efficacy.
2. Conformational Restriction: A cyclopropyl group introduces a degree of conformational restriction compared to a rotatable methyl group. This can impact the binding affinity and selectivity of a compound by favoring a particular conformation that is more optimal for receptor interaction.
3. Electronic Effects: Cyclopropyl groups exhibit unique electronic properties (e.g., "bent bonds" that confer some π-character) which can influence the electron density and reactivity of adjacent functional groups, potentially leading to favorable interactions within the GLP-1R binding site.
4. Known Chemical Principles: The "other references discussing substitutions that preserve or enhance biological activity" (e.g., Yoshino, Kawai, and Talele) would likely teach that such structural modifications (like methyl-to-cyclopropyl) are common strategies in drug discovery to optimize physicochemical and biological properties of lead compounds without necessarily diminishing their core activity. A PHOSITA would understand that small alkyl group modifications, particularly replacements with cyclopropyl, are routine explorations in analog synthesis.

Therefore, starting with the known GLP-1R agonist orforglipron, and armed with the general knowledge in the field (as exemplified by Yoshino, Kawai, and Talele) that cyclopropyl groups can serve as effective replacements for methyl groups to modulate metabolic stability, potency, or other pharmacokinetic properties, a PHOSITA would have been motivated to synthesize compounds incorporating such a change, with a reasonable expectation of achieving a GLP-1R agonist with desirable therapeutic properties. The PTAB's decision to institute the PGR on these grounds supports the contention that such a combination of prior art and motivation for modification would render claims 1 and 24 obvious.

US patent 12234236 has an anticipated expiration date of September 13, 2044.

Patent Term Adjustments (PTA)

Patent Term Adjustment (PTA) provides an extension to the patent term to compensate for administrative delays by the USPTO during the prosecution of a patent application. To be eligible, the USPTO must:

• Issue an office action within 14 months after the application filing.
• Respond to a reply or an appeal within four months after the reply was filed or the appeal was taken.
• Act on an application within four months after a decision by the Patent Trial and Appeal Board (PTAB) or a federal court.
• Issue a patent within four months after payment of an issue fee.
• Issue a patent within 36 months from the filing date of the application.

The term is extended one day for each day beyond these specified periods. However, any accrued PTA can be reduced if the applicant fails to engage in reasonable efforts to conclude prosecution.

Specific information regarding any Patent Term Adjustments (PTA) applied to US patent 12234236 is not available in the provided search results.

Patent Term Extensions (PTE)

Patent Term Extension (PTE) grants additional patent term for patents related to U.S. pharmaceutical products, compensating for the effective loss of patent term due to delays during the FDA drug approval process. Eligibility for PTE requires that a patent claims a drug product, a method of using a drug product, or a method of manufacturing a drug product. PTE is only available for the first approval of an "active ingredient."

Specific information regarding any Patent Term Extensions (PTE) applied to US patent 12234236 is not available in the provided search results.

Continuation and Divisional Applications

The provided patent text indicates that the present disclosure claims benefits from several US provisional applications and Chinese patent applications. While not explicitly labeled as continuation or divisional applications of US12234236, these demonstrate a family of related applications. These include:

• U.S. provisional application No. 63/538,892, filed September 18, 2023.
• U.S. provisional application No. 63/545,615, filed October 25, 2023.
• U.S. provisional application No. 63/603,854, filed November 29, 2023.
• U.S. provisional application No. 63/673,453, filed July 19, 2024.
• US application numbers US19/051,013 (filed 2025-02-11), US19/271,553 (filed 2025-07-16), US19/271,557 (filed 2025-07-16), and US19/271,548 (filed 2025-07-16) are listed as "Pending" with an "Active" legal status. These appear to be continuation or divisional applications as they are linked to the parent application US18/884,965, which is the application number for US12234236B1.

Related Family Members

US patent 12234236 is part of a patent family that includes:

• TW-202521533-A
• WO-2025057134-A2
• WO-2025057134-A3

Additionally, the patent text references numerous Chinese patent applications from which benefits are claimed, further indicating a broader patent family.

Projected Expiration Date

The anticipated expiration date for US patent 12234236 is September 13, 2044.

The following defensive disclosure aims to create prior art by outlining various derivative variations of the technology described in US patent 12234236. The focus is on the compound of Formula (I) and related therapeutic methods, extending its scope into areas that would render future incremental advancements by competitors obvious or non-novel.

Derivative Variations of US12234236

The primary subject of derivation is the compound of Formula (I), a GLP-1R agonist, and its application in therapeutic methods.

1. Material & Component Substitution

Derivative 1.1: Alternative Bicyclic Heteroaryl Moieties for Z2

• Enabling Description: A compound analogous to Formula (I) wherein the Z2 moiety, defined as 5- to 10-membered heteroaryl substituted with one halogen and one C3-15 cycloalkyl or C1-6 alkyl-C3-15 cycloalkyl, is replaced with alternative bicyclic heteroaryl systems. Specific substitutions include replacing the indazolyl group with 5,6,7,8-tetrahydro-1,8-naphthyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, or benzothiazolyl, each maintaining the substitution pattern of one halogen (e.g., fluoro, chloro) and one C3-15 cycloalkyl (e.g., cyclopropyl, cyclohexyl) or C1-6 alkyl-C3-15 cycloalkyl (e.g., cyclopropylmethyl) group. These substitutions are chosen to explore iso(bio)steric replacements while maintaining or modulating GLP-1R binding affinity and efficacy, leveraging known scaffold hopping strategies in medicinal chemistry.
• Specific Technical Terminology: Bicyclic heteroaryl, 5,6,7,8-tetrahydro-1,8-naphthyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, benzothiazolyl, iso(bio)steric replacement, scaffold hopping, GLP-1R binding affinity, efficacy, medicinal chemistry.

classDiagram
    class FormulaI {
        +Z2_Indazolyl
    }
    class Derivative1_1 {
        +Z2_Tetrahydronaphthyridinyl
        +Z2_Pyrrolopyridinyl
        +Z2_Benzothiazolyl
    }
    FormulaI --|> Derivative1_1 : Z2 Moiety Substitution
    Derivative1_1 : +Substituents (Halogen, Cycloalkyl/Alkyl-Cycloalkyl)

Derivative 1.2: Fluoroalkyl/Fluoroalkoxy Substitution for C1-6 Alkyl/Alkoxy Groups

• Enabling Description: A compound of Formula (I) where one or more C1-6 alkyl or C1-6 alkoxy substituents (e.g., on Q1, Q2, R1-R8) are systematically replaced with their corresponding fluoroalkyl (e.g., CF3, CHF2, CH2F) or fluoroalkoxy (e.g., OCF3, OCHF2, OCH2F) analogs. This substitution aims to enhance metabolic stability, lipophilicity, and potentially membrane permeability, which are critical for oral bioavailability and sustained systemic exposure. For example, a phenyl group (Q1) optionally substituted with C1-6 haloalkyl instead of C1-6 alkyl, or a heterocyclic Q2 group substituted with C1-6 haloalkoxy.
• Specific Technical Terminology: Fluoroalkyl, fluoroalkoxy, C1-6 alkyl, C1-6 alkoxy, metabolic stability, lipophilicity, membrane permeability, oral bioavailability, sustained systemic exposure, haloalkyl, haloalkoxy.

graph TD
    A[Original Formula I Structure] --> B{Identify C1-6 Alkyl/Alkoxy Position}
    B -- R_alkyl --> C[Replace with C1-6 Haloalkyl]
    B -- R_alkoxy --> D[Replace with C1-6 Haloalkoxy]
    C --> E[Derivative with Enhanced PK]
    D --> E
    E --> F[In vitro/In vivo Metabolic Stability Assay]

2. Operational Parameter Expansion

Derivative 2.1: Ultra-Low Dose Continuous Infusion for Chronic Management

• Enabling Description: Administration of a compound of Formula (I) via a miniaturized, implantable osmotic pump or transdermal patch system, delivering an ultra-low, constant therapeutic dose (e.g., 0.00001 to 0.0001 mg/kg/day) over extended periods (months to years). This contrasts with intermittent dosing, aiming to maintain steady-state plasma concentrations, minimize peak-trough fluctuations, and reduce side effects associated with high Cmax, particularly for conditions requiring chronic GLP-1R modulation like pre-diabetes or very early-stage obesity. The system would allow for remote programming of infusion rates.
• Specific Technical Terminology: Implantable osmotic pump, transdermal patch, ultra-low dose, constant therapeutic dose, steady-state plasma concentration, peak-trough fluctuations, Cmax, chronic GLP-1R modulation, pre-diabetes, early-stage obesity, remote programming, infusion rates.

flowchart TD
    A[Compound of Formula I] --> B(Micro-reservoir/Formulation)
    B --> C(Miniaturized Osmotic Pump / Transdermal Patch)
    C --> D{Implant / Apply to Patient}
    D --> E[Continuous Ultra-Low Dose Release]
    E --> F[Stable Plasma Concentration]
    F --> G[Chronic GLP-1R Modulation]
    G --> H[Reduced Side Effects]

Derivative 2.2: Pulsatile Dosing for Enhanced Physiological Mimicry

• Enabling Description: A compound of Formula (I) delivered using a pulsatile release pharmaceutical formulation or an electronically controlled pump, designed to mimic the endogenous post-prandial release profile of GLP-1. This involves administering boluses of the compound (e.g., 0.1-1 mg/kg/dose) at specific intervals relative to meal times (e.g., 15-30 minutes before or immediately after), or in response to real-time glucose fluctuations detected by continuous glucose monitoring. This approach aims to maximize acute insulinotropic effects, enhance satiety signaling, and potentially overcome receptor desensitization observed with continuous high-level agonism, for conditions like post-prandial hyperglycemia.
• Specific Technical Terminology: Pulsatile release, electronically controlled pump, endogenous post-prandial release, bolus administration, meal times, continuous glucose monitoring (CGM), insulinotropic effects, satiety signaling, receptor desensitization, post-prandial hyperglycemia.

sequenceDiagram
    participant Patient
    participant CGM_Sensor [Continuous Glucose Monitor]
    participant Smart_Pump [Pulsatile Delivery Pump]
    participant Formula_I [Compound]

    CGM_Sensor ->> Smart_Pump: Real-time Glucose Data
    Patient ->> Smart_Pump: Meal Time Input
    Smart_Pump -->> Smart_Pump: Calculate optimal bolus timing/amount
    Smart_Pump ->> Formula_I: Dispense bolus dose
    Formula_I ->> Patient: Acute GLP-1R activation
    Patient ->> CGM_Sensor: Post-prandial glucose control

3. Cross-Domain Application

Derivative 3.1: Aquaculture Feed Additive for Fish Growth and Health

• Enabling Description: A compound of Formula (I) incorporated as a feed additive in aquaculture for fish species (e.g., salmon, tilapia, carp) to enhance growth rates, improve feed conversion ratio (FCR), and modulate immune response. The compound would be microencapsulated in a water-stable, gastric-resistant coating suitable for aquatic environments (e.g., alginate-chitosan nanoparticles or lipid-based encapsulation) to ensure stability in water and targeted delivery to the fish gut. Dosage would be optimized based on fish species, age, and farming conditions, delivered through commercial feed pellets.
• Specific Technical Terminology: Aquaculture, feed additive, fish growth rates, feed conversion ratio (FCR), immune response, microencapsulation, water-stable coating, gastric-resistant coating, alginate-chitosan nanoparticles, lipid-based encapsulation, targeted delivery, feed pellets.

graph TD
    A[Formula I Compound] --> B(Encapsulation Process)
    B --> C{Water-Stable, Gastric-Resistant Microcapsules}
    C --> D(Aquafeed Production)
    D --> E[Commercial Fish Feed Pellets]
    E --> F[Fish Consumption]
    F --> G[Targeted GLP-1R Activation in Fish Gut]
    G --> H[Enhanced Growth, Improved FCR, Modulated Immunity]

Derivative 3.2: Companion Animal Weight Management (Veterinary)

• Enabling Description: A veterinary pharmaceutical composition containing a compound of Formula (I) specifically formulated for oral administration to companion animals (e.g., dogs, cats) for weight management and treatment of companion animal type 2 diabetes. The formulation would be a palatable, chewable tablet or an oral suspension, optimized for animal pharmacokinetics. Dosage would be calculated based on species, weight, and existing metabolic conditions, with veterinary supervision. This extends the patent's described use in "domestic animals" to a specific therapeutic application in a high-value veterinary market.
• Specific Technical Terminology: Veterinary pharmaceutical, companion animals, weight management, companion animal type 2 diabetes, palatable chewable tablet, oral suspension, animal pharmacokinetics, veterinary supervision.

flowchart TD
    A[Obese/Diabetic Companion Animal] --> B{Veterinary Diagnosis}
    B -- Yes --> C[Prescribe Formula I (Oral Form)]
    C --> D[Animal Ingests Daily Dose]
    D --> E[GLP-1R Activation in Animal]
    E --> F[Reduced Appetite, Improved Glucose Homeostasis]
    F --> G[Weight Loss / Diabetes Management]
    C --> H[Regular Vet Check-up & Dose Adjustment]

Derivative 3.3: Pest Control (Insect Metabolism Modulation)

• Enabling Description: A compound of Formula (I) or a structural analog designed to modulate GLP-1R-like receptors in insect pests (e.g., agricultural pests, disease vectors). The compound would be formulated as a bait or spray, disrupting insect feeding behavior, metabolism, and reproductive cycles. This novel approach to pest control would target metabolic pathways distinct from conventional insecticides, potentially reducing resistance development and improving selectivity. Delivery would involve slow-release matrices or microencapsulated formulations suitable for environmental application.
• Specific Technical Terminology: GLP-1R-like receptors, insect pests, agricultural pests, disease vectors, feeding behavior, metabolism, reproductive cycles, bait formulation, spray formulation, slow-release matrices, microencapsulated formulations, insecticide resistance.

graph TD
    A[Formula I Analog] --> B(Insecticide Formulation)
    B --> C[Environmental Application (Bait/Spray)]
    C --> D[Insect Ingestion/Exposure]
    D --> E[GLP-1R-like Receptor Activation in Insect]
    E --> F{Disrupted Metabolism / Feeding / Reproduction}
    F --> G[Pest Population Reduction]

4. Integration with Emerging Tech

Derivative 4.1: AI-Optimized Compound Synthesis and Process Control

• Enabling Description: The manufacturing process for compounds of Formula (I) controlled and optimized by an AI system. This AI leverages sensor data from reaction vessels (temperature, pressure, pH, reagent addition rates) and real-time analytical data (HPLC, NMR, mass spectrometry) to predict reaction kinetics, optimize yield, control purity, and minimize side-product formation. The AI adjusts process parameters autonomously, learns from previous batch data, and ensures consistent quality. This includes predictive maintenance schedules for synthesis equipment.
• Specific Technical Terminology: AI system, reaction kinetics, yield optimization, purity control, side-product formation, autonomous process control, predictive maintenance, HPLC, NMR, mass spectrometry, reaction vessels, real-time analytical data.

flowchart TD
    A[Raw Material Input] --> B(Reaction Vessel with Sensors)
    B -- Process Data (Temp, pH, Pressure) --> C(Real-time Analytics - HPLC, NMR)
    C -- Analytical Data --> D(AI Process Control Engine)
    D -- Optimization Commands --> B
    D -- Predictive Maintenance --> E[Equipment Maintenance System]
    B --> F[Formula I Output (Optimized Yield/Purity)]

Derivative 4.2: IoT-Enabled Smart Packaging for Adherence and Cold Chain Monitoring

• Enabling Description: Pharmaceutical packaging for a compound of Formula (I) integrated with IoT sensors. Each blister pack or vial contains miniature sensors that detect removal of individual doses, providing adherence data. Additionally, temperature and humidity sensors within the packaging monitor cold chain integrity during storage and transport. This data is wirelessly transmitted to a patient's smartphone app and a cloud-based healthcare platform, allowing for real-time adherence tracking, identification of temperature excursions that might affect drug stability, and automated refill reminders.
• Specific Technical Terminology: IoT sensors, smart packaging, blister pack, vial, miniature sensors, adherence data, temperature sensors, humidity sensors, cold chain integrity, wireless transmission, smartphone app, cloud-based healthcare platform, real-time adherence tracking, temperature excursions, drug stability, automated refill reminders.

sequenceDiagram
    participant Manufacturer
    participant Distributor
    participant Pharmacy
    participant Patient
    participant Smart_Packaging [IoT-Enabled Packaging]
    participant Cloud_Platform [Healthcare Cloud]

    Manufacturer->>Smart_Packaging: Integrates sensors
    Smart_Packaging->>Distributor: Monitors Cold Chain
    Distributor->>Pharmacy: Monitors Cold Chain
    Pharmacy->>Patient: Dispenses with Adherence Sensor
    Patient->>Smart_Packaging: Takes Dose
    Smart_Packaging->>Patient: Reminds Next Dose (App)
    Smart_Packaging->>Cloud_Platform: Transmits Adherence/Temp Data
    Cloud_Platform->>Pharmacy: Alerts on Non-Adherence/Excursions
    Cloud_Platform->>Manufacturer: Quality & Stability Insights

Derivative 4.3: Blockchain for Patient Consent and Data Governance in Clinical Trials

• Enabling Description: Clinical trials involving a compound of Formula (I) utilize a decentralized blockchain system for managing patient informed consent and secure data sharing. Each patient's consent for data usage (e.g., physiological responses, adverse events, outcomes) is recorded as an immutable transaction on a blockchain. Patients retain control over their data, granting or revoking access to specific researchers or institutions through cryptographic keys. This ensures data provenance, auditability, and compliance with regulations like GDPR, while facilitating secure, transparent, and efficient multi-site clinical research.
• Specific Technical Terminology: Decentralized blockchain system, patient informed consent, secure data sharing, immutable transaction, cryptographic keys, data provenance, auditability, GDPR compliance, multi-site clinical research, physiological responses, adverse events, clinical trial outcomes.

graph TD
    A[Patient] --> B{Grant Consent for Data Sharing}
    B -- Signed Consent (Cryptographic) --> C(Blockchain Network)
    C --> D[Immutable Consent Record]
    E[Clinical Site A] -- Uploads Anonymized Data --> C
    F[Clinical Site B] -- Uploads Anonymized Data --> C
    G[Researcher] -- Requests Access (Validated by Blockchain) --> C
    C -- Grants Access (if permitted) --> G[Access to Data]
    C -- Revokes Access --> A

5. The "Inverse" or Failure Mode

Derivative 5.1: GLP-1R Antagonist for Hypoglycemia Reversal

• Enabling Description: A structurally modified compound of Formula (I) engineered to function as a selective GLP-1R antagonist. This "inverse" compound would competitively bind to the GLP-1 receptor without activating it, thus blocking the effects of endogenous GLP-1 or other GLP-1R agonists. Such an antagonist would be useful for rapidly reversing severe hypoglycemia, particularly in patients over-treated with insulin or GLP-1R agonists, or in rare cases of GLP-1oma. The compound would be formulated for rapid intravenous administration to ensure swift onset of action in emergency situations.
• Specific Technical Terminology: GLP-1R antagonist, competitive binding, selective antagonist, hypoglycemia reversal, endogenous GLP-1, GLP-1R agonists, GLP-1oma, rapid intravenous administration, swift onset of action.

stateDiagram-v2
    state "Normal State" as Normal
    state "Hypoglycemic Event" as Hypoglycemia
    state "GLP-1R Antagonist Administered" as AntagonistAdmin
    state "GLP-1R Blocked" as ReceptorBlocked
    state "Glucose Levels Normalize" as GlucoseNormal

    Normal --> Hypoglycemia : Insulin Overtreatment / GLP-1oma
    Hypoglycemia --> AntagonistAdmin : Emergency Intervention
    AntagonistAdmin --> ReceptorBlocked : Rapid Binding
    ReceptorBlocked --> GlucoseNormal : Block GLP-1R activity -> increased glucose
    GlucoseNormal --> Normal : Recovery

Derivative 5.2: Self-Limiting Prodrug with pH-Sensitive Deactivation

• Enabling Description: A prodrug of a compound of Formula (I) designed with a pH-sensitive linker that undergoes rapid hydrolysis and deactivation at physiological pH values slightly outside the normal range (e.g., below pH 6.0 or above pH 8.0), or in specific pathological conditions (e.g., acidic tumor microenvironment). The prodrug would release the active Formula (I) slowly under normal conditions, but in case of systemic acidosis (e.g., severe diabetic ketoacidosis) or alkalosis, the prodrug would rapidly break down into inactive metabolites, thereby reducing the effective circulating concentration of the active drug and preventing exacerbation of metabolic distress or other adverse effects.
• Specific Technical Terminology: Prodrug, pH-sensitive linker, rapid hydrolysis, deactivation, physiological pH, pathological conditions, acidic tumor microenvironment, systemic acidosis, severe diabetic ketoacidosis, alkalosis, inactive metabolites, circulating concentration, metabolic distress, adverse effects.

graph TD
    A[Prodrug (Formula I Linked)] --> B{Normal pH (6.5-7.5)?}
    B -- Yes --> C[Slow Active Drug Release]
    C --> D[Therapeutic Effect]
    B -- No (pH < 6.0 or pH > 8.0) --> E[Rapid Hydrolysis / Deactivation]
    E --> F[Inactive Metabolites]
    F --> G[Self-Limiting Safety Mechanism]
    D --> G

5.3: Limited-Functionality Diagnostic Tracer (Non-Activating)

• Enabling Description: A non-activating derivative of a compound of Formula (I) designed exclusively as a GLP-1R imaging tracer, incorporating a non-radioactive tag (e.g., a fluorescent probe, a heavy atom for X-ray contrast, or a paramagnetic metal chelator for MRI). This compound would bind selectively to GLP-1R but lack intrinsic agonist activity. Its purpose is to visualize GLP-1R distribution and density in tissues (e.g., pancreas, brain, heart) for diagnostic purposes (e.g., early detection of beta-cell loss in diabetes, localization of GLP-1R expressing tumors), without altering physiological function. The non-activating nature ensures safety and prevents confounding therapeutic effects during imaging.
• Specific Technical Terminology: Non-activating derivative, GLP-1R imaging tracer, non-radioactive tag, fluorescent probe, heavy atom, X-ray contrast, paramagnetic metal chelator, MRI, selective binding, intrinsic agonist activity, GLP-1R distribution, GLP-1R density, pancreas, brain, heart, beta-cell loss, GLP-1R expressing tumors, diagnostic imaging.

classDiagram
    class FormulaI_Active {
        +Binds_GLP-1R()
        +Activates_GLP-1R()
        +Therapeutic_Effect()
    }
    class FormulaI_Tracer {
        +Binds_GLP-1R()
        -Activates_GLP-1R()
        +Imaging_Probe_Attached()
        +Diagnostic_Imaging()
    }
    FormulaI_Active <|-- FormulaI_Tracer : Structural Analogue
    FormulaI_Tracer : Binds without activation

Combination Prior Art Scenarios

These scenarios combine the inventive concepts of US12234236 with existing open-source standards, demonstrating how the patent's technology could be integrated with readily available, non-proprietary frameworks.

Combination Prior Art Scenario 1: Formula (I) + Open-Source Electronic Health Record (EHR) Standard (FHIR)

• Enabling Description: The use of a compound of Formula (I) for treating GLP-1R-mediated diseases, where patient demographics, diagnosis (e.g., T2DM, obesity, NASH), prescribed dosage, administration route (e.g., oral, subcutaneous), observed therapeutic outcomes (e.g., HbA1c, weight, liver fat content), and any adverse drug reactions are meticulously documented within an open-source Electronic Health Record (EHR) system. This system adheres strictly to the Fast Healthcare Interoperability Resources (FHIR) standard (e.g., version R4 or newer) for data exchange. This enables seamless and secure interoperability with other FHIR-compliant systems (e.g., pharmacies, laboratories, insurance providers), facilitating real-world evidence generation, population health management, and personalized treatment adjustments based on standardized, machine-readable data. The integration would involve FHIR resources such as 'MedicationRequest', 'Observation', 'Condition', and 'Patient'.
• Specific Technical Terminology: Electronic Health Record (EHR), Fast Healthcare Interoperability Resources (FHIR) standard, FHIR R4, GLP-1R-mediated diseases, T2DM, obesity, NASH, HbA1c, liver fat content, adverse drug reactions, interoperability, real-world evidence, population health management, personalized treatment, machine-readable data, FHIR resources (MedicationRequest, Observation, Condition, Patient).

Combination Prior Art Scenario 2: Formula (I) Manufacturing + Open-Source Laboratory Automation (Python/Open-Robot Control)

• Enabling Description: The large-scale synthesis of a compound of Formula (I) utilizing an automated flow chemistry platform, where all liquid handling, reagent addition, temperature control, and in-line analytical sampling are orchestrated by an open-source laboratory automation system. This system is programmed using Python-based scripting frameworks (e.g., PyLabware, opentrons-api) and communicates with robotic components via open-robot control protocols (e.g., ROS - Robot Operating System). Real-time process data is streamed and stored in an open-source database (e.g., PostgreSQL). This allows for highly reproducible and scalable synthesis, rapid experimentation with reaction parameters, and decentralized sharing of synthesis protocols across different research and manufacturing sites without proprietary software lock-in.
• Specific Technical Terminology: Automated flow chemistry platform, liquid handling, reagent addition, temperature control, in-line analytical sampling, open-source laboratory automation system, Python-based scripting frameworks, PyLabware, opentrons-api, open-robot control protocols, ROS (Robot Operating System), PostgreSQL, reproducible synthesis, scalable synthesis, decentralized sharing, synthesis protocols, proprietary software lock-in.

Combination Prior Art Scenario 3: Formula (I) Drug Design + Open-Source Cheminformatics & Molecular Modeling Tools

• Enabling Description: The rational design, virtual screening, and lead optimization of novel GLP-1R agonists based on the scaffold of Formula (I), performed entirely using open-source cheminformatics and molecular modeling software. This workflow includes:
  1. Ligand preparation and 2D/3D descriptor generation using RDKit.
  2. Molecular docking simulations against publicly available GLP-1R crystal structures (e.g., from PDB) using AutoDock Vina or smina.
  3. Molecular dynamics (MD) simulations to assess ligand-receptor stability and binding free energies with GROMACS.
  4. ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) prediction using open-source machine learning models trained on publicly accessible datasets.
     This combination demonstrates a comprehensive, cost-effective, and transparent in silico drug discovery pipeline that can be readily replicated and extended by any researcher, accelerating the development of further GLP-1R modulators.
• Specific Technical Terminology: Rational drug design, virtual screening, lead optimization, GLP-1R agonists, open-source cheminformatics, molecular modeling software, ligand preparation, 2D/3D descriptor generation, RDKit, molecular docking simulations, GLP-1R crystal structures, PDB, AutoDock Vina, smina, molecular dynamics (MD) simulations, GROMACS, ADMET prediction, machine learning models, in silico drug discovery pipeline.